A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

Conditions

• Diabetes Mellitus, Type 2

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• NNC0480-0389 — DRUG
  A weekly dose of NNC0480-0389, dose increased in each cohort. The study will last for about 41weeks.
• Semaglutide — DRUG
  A weekly dose of semaglutide, same dose in each cohort. The study will last for about 41weeks.
• Placebo (NNC080-0389) — DRUG
  A weekly dose of placebo (NNC0480-0389). The study will last for about 41weeks.
• Placebo (semaglutide) — DRUG
  A weekly dose of placebo (semaglutide). The study will last for about 41weeks.

Study Details

This study is looking at semaglutide in combination with a potential new medicine (NNC0480-0389) in people with type 2 diabetes. The study is being conducted to see how well semaglutide, in combination with different doses of NNC0480-0389, work to lower blood sugar levels. Results from this study will be used to select the doses of the two medicines for other studies. Participants will either get: Semaglutide (a medicine doctors can already prescribe for treatment of type 2 diabetes) in combination with NNC0480-0389 (a potential new medicine) or placebo (a 'dummy' medicine that looks like the medicines but without any medicine). NNC0480-0389 alone, or semaglutide alone which treatment participant get is decided by chance. Participant will need to take 2-3 injections once every week during the study. One injection will be with semaglutide or placebo and 1-2 injections will be with NNC0480-0389 or placebo. Participant must inject the study medicines themself into the stomach, thigh, or upper arm. The study will last for about 41weeks. Participant will have 20 clinic visits. Participant will have blood samples taken at all clinic visits. At 3 clinic visits, participant will also have an electrocardiogram (ECG). This is a test to check participants heart. Participant will have their eyes checked before or at the start of the study and at the end of the study. Women can only take part in the study if they are not able to become pregnant

Key Dates

Start date

Nov 29, 2021

Status verified

Mar 2026

Primary completion

Feb 13, 2023

Completion

Mar 23, 2023

Study Design

Enrollment

500 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: 2.4 mg semaglutide + 2.4 mg NNC0480-0389
  subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide.
• Placebo Comparator: Placebo (semaglutide) + placebo ( 2.4 mg NNC0480-0389)
  subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
• Experimental: 2.4 mg semaglutide + 7.2 mg NNC0480-0389
  subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
• Experimental: 2.4 mg semaglutide + 12.0 mg NNC0480-0389
  subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
• Experimental: 2.4 mg semaglutide + 21.6 mg NNC0480-0389
  subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. semaglutide
• Experimental: NNC0480-0389 + placebo (semaglutide)
  subjects will receive once weekly subcutaneous (s.c., under the skin) dose of NNC0480-0389 co-administered with s.c. placebo (semaglutide)
• Placebo Comparator: Placebo (semaglutide) + placebo ( 7.2 mg NNC0480-0389)
  subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
• Placebo Comparator: Placebo (semaglutide) + placebo ( 12.0 mg NNC0480-0389)
  subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
• Placebo Comparator: Placebo (semaglutide) + placebo ( 21.6 mg NNC0480-0389)
  subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. placebo (semaglutide).
• Experimental: Semaglutide 2.4 mg + placebo (NNC0480-0389)
  subjects will receive once weekly subcutaneous (s.c., under the skin) dose of placebo (NNC0480-0389) co-administered with s.c. semaglutide.

Primary Outcome Measure

Change From Baseline in Glycosylated Haemoglobin (HbA1c) [ Time Frame: Baseline (week 0), (week 34) ]

Locations (71)

Related coverage on Hipa.ai

• Trial results posted: NCT05144984
  Semaglutide · Apr 9, 2026 · ClinicalTrials.gov

Find similar trials in Anniston, AL

Related Studies

• Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
  Recruiting · The University of Texas Health Science Center at San Antonio · San Antonio, Texas
• Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.
  PHASE2 · Enrolling By Invitation · Columbia University · New York, New York
• Phenotyping Genetic Risk for Type 2 Diabetes
  Recruiting · University of Pennsylvania · Philadelphia, Pennsylvania
• Use of CGM in Kidney Transplant Recipients
  Recruiting · University of California, Davis · Sacramento, California